Verastem (NASDAQ: VSTM) insider transactions
In the twelve months to 10 November 2026, executives and directors of Verastem reported 32 open-market sales of 135,587 shares ($1.1m) and 0 open-market purchases, by 6 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 3 November 2026 | Paterson Dan | President and CEO | Open-market sale, 10b5-1 plan | −1,299 | $9.60 | 651,413 | Form 4 |
| 1 October 2026 | Calkins Daniel | Chief Financial Officer | Open-market sale, 10b5-1 plan | −2,566 | $8.00 | 123,781 | Form 4 |
| 1 October 2026 | Paterson Dan | President and CEO | Open-market sale, 10b5-1 plan | −44,121 | $8.00 | 652,712 | Form 4 |
| 30 September 2026 | Calkins Daniel | Chief Financial Officer | Grant or award, 10b5-1 plan | −8,333 | — | 126,347 | Form 4 |
| 30 September 2026 | Paterson Dan | President and CEO | Grant or award, 10b5-1 plan | −106,893 | — | 696,833 | Form 4 |
| 21 September 2026 | Calkins Daniel | Chief Financial Officer | Open-market sale, 10b5-1 plan | −55 | $7.70 | 118,014 | Form 4 |
| 3 August 2026 | Paterson Dan | President and CEO | Open-market sale, 10b5-1 plan | −1,302 | $5.81 | 589,940 | Form 4 |
| 22 June 2026 | Calkins Daniel | Chief Financial Officer | Open-market sale, 10b5-1 plan | −4,032 | $4.18 | 117,295 | Form 4 |
| 22 June 2026 | Calkins Daniel | Chief Financial Officer | Open-market sale, 10b5-1 plan | −57 | $4.13 | 117,238 | Form 4 |
| 22 June 2026 | Paterson Dan | President and CEO | Open-market sale, 10b5-1 plan | −20,871 | $4.18 | 591,242 | Form 4 |
| 21 May 2026 | Bailey Michael P | Director | Grant or award | +108,000 | — | 108,000 | Form 4 |
| 21 May 2026 | Johnson John | Director | Grant or award | +36,000 | — | 52,666 | Form 4 |
| 21 May 2026 | Bunn Paul A. | Director | Grant or award | +36,000 | — | 44,333 | Form 4 |
| 21 May 2026 | Kapur Anil | Director | Grant or award | +36,000 | — | 52,666 | Form 4 |
| 21 May 2026 | Robertson Michelle | Director | Grant or award | +36,000 | — | 52,666 | Form 4 |
| 21 May 2026 | Rowinsky Eric K | Director | Grant or award | +36,000 | — | 52,666 | Form 4 |
| 21 May 2026 | Stuglik Brian M | Director | Grant or award | +36,000 | — | 137,147 | Form 4 |
| 21 May 2026 | Tollefson Karin Anna | Director | Grant or award | +36,000 | — | 52,666 | Form 4 |
| 4 May 2026 | Paterson Dan | President and CEO | Open-market sale, 10b5-1 plan | −806 | $5.82 | 612,113 | Form 4 |
| 20 March 2026 | Calkins Daniel | Chief Financial Officer | Grant or award, 10b5-1 plan | −57 | $5.74 | 121,327 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Verastem page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.